Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors

Psychiatric Services

Volumn 66, Issue 12, 2015, Pages 1333-1340

  Bali, Vishal ^a   Chatterjee, Satabdi ^a   Carnahan, Ryan M ^b   Chen, Hua ^a   Johnson, Michael L ^a   Aparasu, Rajender R ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANALGESIC AGENT; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; CHOLINESTERASE INHIBITOR; GASTROINTESTINAL AGENT; HEMATOLOGIC AGENT; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PAROXETINE; RESPIRATORY TRACT AGENT; SEROTONIN UPTAKE INHIBITOR; TOPICAL AGENT;

ACUTE HEART INFARCTION; AGE; AGED; ALCOHOLISM; ANEMIA; ANXIETY DISORDER; ARTICLE; ASTHMA; BACKACHE; BIPOLAR DISORDER; CATARACT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG DEPENDENCE; DRUG USE; DYSPHAGIA; ENDOCARDITIS; EXTRAPYRAMIDAL SYNDROME; FALLING; FEMALE; FIBROMYALGIA; GENDER; GLAUCOMA; GOUT; HEART ARRHYTHMIA; HIP FRACTURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INSOMNIA; ISCHEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; NEOPLASM; NURSING HOME PATIENT; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; PARKINSON DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PNEUMONIA; PROPENSITY SCORE; PROSTATE HYPERTROPHY; RACE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SAMPLE SIZE; SCHIZOPHRENIA; STOMACH DISEASE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; ULCER; CAUSALITY; COMORBIDITY; DEPRESSIVE DISORDER; HOME FOR THE AGED; NURSING HOME; PROPORTIONAL HAZARDS MODEL; RISK; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAUSALITY; COHORT STUDIES; COMORBIDITY; DEMENTIA; DEPRESSIVE DISORDER; FEMALE; HOMES FOR THE AGED; HUMANS; MALE; NURSING HOMES; PAROXETINE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 84948757871     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201500011     Document Type: Article

References (56)

1. Kamat SM, Kamat AS, Grossberg GT: Dementia risk prediction: are we there yet? Clinics in Geriatric Medicine 26:113-123, 2010
2. Sherrod RA, Collins A, Wynn S, et al: Dissecting dementia, depression, and drug effects in older adults. Journal of Psychosocial Nursing and Mental Health Services 48:39-47, 2010
3. Steffens DC, Potter GG: Geriatric depression and cognitive impairment. Psychological Medicine 38:163-175, 2008
4. Brookmeyer R, Johnson E, Ziegler-Graham K, et al: Forecasting the global burden of Alzheimers disease: Alzheimers and dementia. Journal of the Alzheimers Association 3:186-191, 2007
5. Thies W, Bleiler L: Alzheimers disease facts and figures: Alzheimers and dementia. Journal of the Alzheimers Association 7:208-244, 2011
6. Middleton LE, Yaffe K: Promising strategies for the prevention of dementia. Archives of Neurology 66:1210-1215, 2009
7. Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatrica Scandinavica 76:465-479, 1987
8. Ownby RL, Crocco E, Acevedo A, et al: Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Archives of General Psychiatry 63:530-538, 2006
9. Jorm AF, Jolley D: The incidence of dementia: a meta-analysis. Neurology 51:728-733, 1998
10. Christensen H, Griffiths K, Mackinnon A, et al: A quantitative review of cognitive deficits in depression and Alzheimer-Type dementia. Journal of the International Neuropsychological Society 3:631-651, 1997
11. Williams JW, Plassman BL, Burke J, et al: Preventing Alzheimers Disease and Cognitive Decline. Evidence Report/Technology Assessment no 193. Rockville, Md, Agency for Healthcare Research and Quality, April 2010
12. Campbell NL, Boustani MA, Lane KA, et al: Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 75:152-159, 2010
13. Carrire I, Fourrier-Reglat A, Dartigues JF, et al: Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Archives of Internal Medicine 169:1317-1324, 2009
14. Campbell N, Boustani M, Limbil T, et al: The cognitive impact of anticholinergics: a clinical review. Clinical Interventions in Aging 4:225-233, 2009
15. Alexopoulos GS, Katz IR, Reynolds CF 3rd, et al: Pharmacotherapy of depressive disorders in older patients. Postgraduate Medicine Spec No Pharmacotherapy:1-86, 2001
16. Salzman C, Small GW: Treatment of depression with new and atypical antidepressants; in Clinical Geriatric Psychopharmacology. Edited by Salzman C. Philadelphia, Lippincott, Williams and Wilkins, 2005
17. Gartlehner G, Hansen RA, Morgan LC, et al: Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Annals of Internal Medicine 155:772-785, 2011
18. Gartlehner G, Thieda P, Hansen RA, et al: Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Safety 31:851-865, 2008
19. Goodnick PJ, Goldstein BJ: Selective serotonin reuptake inhibitors in affective disorders-I. basic pharmacology. Journal of Psychopharmacology 12(suppl B):S5-S20, 1998
20. Sanchez C, Reines EH, Montgomery SA: A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? International Clinical Psychopharmacology 29:185-196, 2014
21. Owens MJ, Morgan WN, Plott SJ, et al: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology and Experimental Therapeutics 283:1305-1322, 1997
22. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society 60:616-631, 2012
23. Karkare SU, Bhattacharjee S, Kamble P, et al: Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. American Journal of Geriatric Pharmacotherapy 9:109-119, 2011
24. Chatterjee S, Aparasu RR, Carnahan RM, et al: Prevalence of anticholinergic medication use among elderly nursing home residents with depression. Value in Health 17:A211, 2014
25. Bali V, Aparasu RR, Johnson ML, et al: Risk of dementia associated with the use of paroxetine among the elderly nursing home patients with depression. Value in Health 17:A209, 2014
26. Crystal S, Gaboda D, Lucas J, et al: Assessing medication exposures and outcomes in the frail elderly: assessing research challenges in nursing home pharmacotherapy. Medical Care 48(suppl):S23-S31, 2010
27. Hanlon JT, Donohue J: Medicare Part D data: a valuable tool for pharmacoepidemiology and pharmacoeconomic research. American Journal of Geriatric Pharmacotherapy 8:483-484, 2010
28. Identifiable Data Files. Baltimore, Centers for Medicare and Medicaid Services. Available at www.cms.hhs.gov/IdentifiableDataFiles/02-StandardAnalyticalFiles.asp. Accessed Oct 30, 2014
29. Thorpe CT, Thorpe JM, Kind AJ, et al: Receipt of monitoring of diabetes mellitus in older adults with comorbid dementia. Journal of the American Geriatrics Society 60:644-651, 2012
30. Schneider KM, ODonnell BE, Dean D: Prevalence of multiple chronic conditions in the United States Medicare population. Health and Quality of Life Outcomes 7:82:1-11, 2009
31. Fung V, Brand RJ, Newhouse JP, et al: Using Medicare data for comparative effectiveness research: opportunities and challenges. American Journal of Managed Care 17:488-496, 2011
32. Cantrell CR, Eaddy MT, Shah MB, et al: Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Medical Care 44: 300-303, 2006
33. Cramer JA, Roy A, Burrell A, et al: Medication compliance and persistence: terminology and definitions. Value in Health 11:44-47, 2008
34. Liu X, Chen Y, Faries DE: Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. ClinicoEconomics and Outcomes Research 3:63-72, 2011
35. Baser O: Too much ado about propensity score models? Comparing methods of propensity score matching. Value in Health 9:377-385, 2006
36. Brookhart MA, Schneeweiss S, Rothman KJ, et al: Variable selection for propensity score models. American Journal of Epidemiology 163:1149-1156, 2006
37. Aparasu RR, Chatterjee S, Mehta S, et al: Risk of death in dualeligible nursing home residents using typical or atypical antipsychotic agents. Medical Care 50:961-969, 2012
38. Chatterjee S, Chen H, Johnson ML, et al: Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. American Journal of Geriatric Pharmacotherapy 10:83-94, 2012
39. Chatterjee S, Chen H, Johnson ML, et al: Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Drugs and Aging 29:807-817, 2012
40. Aparasu RR, Chatterjee S, Chen H: Risk of hospitalization and use of first-versus second-generation antipsychotics among nursing home residents. Psychiatric Services 65:781-788, 2014
41. Parson LS: Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Edmonds, Wash, Ovation Research Group, 2001. Available at www2.sas.com/proceedings/sugi26/p214-26.pdf
42. SAS 9.3 Guide to Software Updates. Cary, NC, SAS Institute, Inc, 2011
43. Lin DY, Wei L-J: The robust inference for the Cox proportional hazards model. Journal of the American Statistical Association 84: 1074-1078, 1989
44. Austin PC: The performance of different propensity score methods for estimating marginal hazard ratios. Statistics in Medicine 32: 2837-2849, 2013
45. Gayat E, Resche-Rigon M, Mary JY, et al: Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharmaceutical Statistics 11:222-229, 2012
46. Tune LE: Anticholinergic effects of medication in elderly patients. Journal of Clinical Psychiatry 62(suppl 21):11-14, 2001
47. Feinberg M: The problems of anticholinergic adverse effects in older patients. Drugs and Aging 3:335-348, 1993
48. Kemper RF, Steiner V, Hicks B, et al: Anticholinergic medications: use among older adults with memory problems. Journal of Gerontological Nursing 33:21-29, 2007
49. Rmillard AJ: A pharmacoepidemiological evaluation of anticholinergic prescribing patterns in the elderly. Pharmacoepidemiology and Drug Safety 5:155-164, 1996
50. Beers MH, Ouslander JG, Rollingher I, et al: Explicit criteria for determining inappropriate medication use in nursing home residents. Archives of Internal Medicine 151:1825-1832, 1991
51. Beers MH: Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Archives of Internal Medicine 157:1531-1536, 1997
52. Fick DM, Cooper JW, Wade WE, et al: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Archives of Internal Medicine 163:2716-2724, 2003
53. Shrank WH, Polinski JM, Avorn J: Quality indicators for medication use in vulnerable elders. Journal of the American Geriatrics Society 55(suppl 2):S373-S382, 2007
54. Tamblyn R, Lavoie G, Petrella L, et al: The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Qubec. Journal of Clinical Epidemiology 48:999-1009, 1995
55. Kirking D, Ammann M, Harrington C: Comparison of medical records and prescription claims files in documenting prescription medication therapy. Journal of Pharmacoepidemiology 5:3-16, 1996
56. Crocco EA, Castro K, Loewenstein DA: How late-life depression affects cognition: neural mechanisms. Current Psychiatry Reports 12:34-38, 2010